*** VIVK is Lookin to Rebound to Higher Highs ***

11/16/2009 1:49 PM

Penny Stocks by: Free Hot Penny Stocks

Buy VIVK Online for $0. Trade stocks for free on Zecco.com.

VIVK is starring in our face and SCREAMING VALUE!!!

VIVK has hit a high in the .60`s and has pulled back in the mid .50`s for
a nice reload!!!

VIVK is on the uptrend for the week and we are looking for higher HIGHS,
potentially profit in the .75 to .80 area!!!!

VIVK trading that high would mean a Potential 50% Gain from this level!!!

STAY TUNED FOR OUR NEXT PICK TONIGHT. VIVK is a KEEPER THIS WEEK!

*** VIVK.OB***

Our Latest Pick - VIVK - is using its diversity to Make a Grab at a $ 1.9
Billion Marketplace!!!

VIVK is worth the research, attention and investment right now!!! Conduct
your own research starting with the basic information below. This company
is The Real Deal!!!

About Vivakor, Inc.
Vivakor, Inc. is a transdisciplinary research company that develops and
acquires products in the fields of molecular medicine, electro-optics,
biological handling and natural and formulary compounds. Vivakor also
provides contract research services for third parties.
Vivakor`s business model is to be a research hub focused on areas that
have both an identified scientific need and a substantial market
opportunity with a significant market. This approach is intended to provide
the necessary environment of transdisciplinary collaboration and
cross-pollination to advance research and technology acquisition. Vivakor`s
mission is to advance or acquire distinct intellectual property and
technologies that improve the quality of life for individual patients,
researchers, clinicians and consumers. Vivakor believes that the
development and commercialization of substantive technologies and cures for
complex human conditions, illnesses and diseases require a sophisticated
approach with contribution from many areas of business and scientific
expertise. Vivakor`s research and the technology it acquires are anchored
by its relationship with collaborative partners and product-specific
commercialization strategies. From the commencement of product conception
or acquisition, through development and commercialization, the Company
expects to have collaborative partners or licensing arrangements in place
for each of its products. Vivakor expects this model to provide several
advantages, including: (i) a more efficient research and development
process; (ii) a quicker time to market after completion of development; and
(iii) the value-add growth to the hub company, Vivakor, through
commercialization and subsidiary spin-off.
Vivakor has commenced developing numerous products and currently has one
pending utility patent. In October, 2008, it acquired a patented MRI
software technology that it intends to develop. Vivakor generally intends
to commercialize its products, after completion of development and any
required regulatory approvals, primarily through one of three methods: (i)
a sale of the technology; (ii) licensing of the product to a manufacturer
or distributor or; (iii) by directly manufacturing, marketing and selling
the products.
Product Research Divisions
Vivakor`s research efforts are divided into four primary areas of medical
and biotechnological development. These are:
1. Molecular Medicine. The goal of this division centers on the
development of biologically relevant molecules, tests and methods and their
application in the practice of medicine.
Vivakor plans to translate systems biology (genomics, proteomics,
metabalomics, etc.) insights of the molecular and cellular basis of disease
into commercializable theranostic (diagnostic/therapeutic) products.
Vivakor scientists will be participants in the discovery and development of
new drugs and the early diagnosis of disease states.
The central aim of the molecular medicine division is cancer detection
and wound healing, which we anticipate will lead to the development of
customized treatments. Research in stem cell biology and nuclear
reprogramming is a critical element in this research.
2. Electro-Optics. This division is charged with the development of
biomedical and related consumer products that incorporate optical and
electronic engineering. Vivakor has actively designed, built and tested
several new electro-optic devices to reach previously un-served or
underserved areas of the biomedical device market and believes the market
potential during the first 12 months of commercialization of these products
is over $15 million. Products scheduled for development in this area
include:

- VivaSight: a digital photorefractor that is intended to modernize child
vision screening. Approval has been granted from Western Institutional
Review Board (20080731) to conduct human validation studies of the
VivaSight technology on children. This study is currently being conducted
at The University of Iowa Hospitals and Clinics.
- Clinical Biomolecular Sensor (CBS): a label free multiplexed approach
for use in the detection and diagnosis of complex human conditions (cancer,
infectious diseases, cardiovascular disease, metabolic disorders, auto
immune and inflammatory diseases)Multi-spectral Imaging: devices to examine
burn degree and cutaneous melanoma and
- Spectroscopic devices: to track wound healing and ear infection. With
the acquisition of HealthAmerica`s SLICES(TM) technology, the Company plans
to adapt and upgrade this technology to produce enhanced MRI images, which
are expected to improve MRI resolution while providing additional data such
as blood flow velocity in imaged tissues. The Company believes its
potential market share for this product is over $300 million annually .
3. Biological Handling. Vivakor has developed commercial products for
cryogengenic preservation, and storage through its VivaThermic Cryovials
(USPTO Utility Patent # 12423998) which are currently being sold and have
improved temperature control and were designed to improve cryopreservation
and thawing of sensitive biological material. Vivakor expects that the
market potential for its products is over $10 million over the next 12
months. It plans to continue to explore new techniques to improve methods
and products employed for cryogenic preservation, storage and handling.
Future research plans for this division include:

- stem cell specific improved cryovials;
- cryogenic devices for temperature maintenance and sample transport);
- a cryogenic biopsy device (Cryopsy); and
- improved modular cryogenic freezer designs. 4. Natural and Formulary
Products. This division plans to focus on the investigation, validation and
adaptation of medical herbalism or botanical medicine. The Company has
already developed a series of nutraceutical formulations, including
VivaBlend, and plan to develop additional nutraceuticals, botanicals and
supplements. Vivakor recently received a 25,000 unit purchase order for one
of our products from Regeneca, International. Future products for this
division include:

- fruit and vegetable extract for the protection of digestive system
- fresh fruit and vegetable extract for antioxidant supplements; and
- jam and jelly formula to contain both antioxidant supplements as well as
bone & cartilage supplements for healthy joints More information can be
found about Vivakor at

www.vivakor.com.
About Regeneca International, Inc.
Regeneca(TM) International, Inc. was formed to create and commercialize
products that help consumers improve their health, battle the signs and
symptoms of aging and to assist you "regenerate their life" through its
family of natural, organic and phytochemical infused products. The
corporate creed is to regenerate the human genetic environment through
ecology centric science. All REGENECA(TM) products must fit the highest
standard of conservation, and reduced carbon footprint. The products must
also work to preserve and promote the user`s health at the most elemental
level of life; the genetic level. The Company`s products and philosophy are
designed to reconnect the consumer to the Earth`s source of healing
properties, but with a symbiotic approach. This is the Company`s "Whole
Earth, Whole Body Approach to Health."
Already a market presence in the multibillion dollar nutraceutical
market, Regeneca`s proprietary, direct to consumer; marketing strategy has
pushed the company to the forefront of emerging consumer product companies.
Regeneca anticipates at least a 500% increase in sales in 2010 and a
similar increase in 2011.
More information can be found about Regeneca International, Inc. at

www.regeneca.com .

Vivakor is a biomedical/biotechnology company with transdisciplinary
research that develops and acquires products in the fields of molecular
medicine, electro-optics, biological handling and natural and formulary
compounds, which extend or improve life.

VIVK information can be found at

www.vivakor.com.

VIVK has seen a tremendous upswing in terms of volume this past week and
our analysts have only good things to say about Vivakors future.

VIVK produced gains of about 20% in the past few days with plenty more
potential in the upcoming weeks!!!

Vivakor Inc. has released exciting news that should have our Members keyed
up on this new alert!!!

Wednesday Nov. 11, 2009 - Vivakor Announces Distribution & Purchase Order
Contract with Regeneca International, Inc. For Cutting-Edge Nutraceutical
Formulation

The Company today announced it has completed an exclusive distribution
agreement with consumer product specialist, Regeneca International, Inc.
(
www.regeneca.com) for one of its proprietary, cutting-edge nutraceutical
formulations. In conjunction with this agreement was an immediate purchase
order from Regeneca for 25,000 units of the product. Both companies hope
this agreement initiates a long term relationship for product
commercialization. This purchase also represents to another substantial
revenue stream for Vivakors emerging nutraceutical division. Vivakor CEO
Tannin Fuja expressed his enthusiasm for the transaction. We are very
excited for the possibilities of Vivakors line of nutraceutical
products. Worldwide demand for nutraceutical products is expected to exceed
$15 billion and Vivakor plans on being a substantial player in that
market.

Dr. Fuja continued, We are particularly pleased to include in our new
formulation the powerful, super-antioxidant star Yumberry (yang-mei in
Chinese) also known as red bayberry thats harvested from one
hundred-year-old trees and the flavonoid-rich concord grape shown to
contain potent antioxidants that may protect against oxidative stress and
reduce the risk of free radical damage and chronic diseases.

Regenecas President, Larry Walter gave his thoughts on the purchase.
From our standpoint, this transaction makes a great deal of sense. The
pilot program we completed with Vivakor demonstrated great promise for the
product from both a commercial and personal health perspective. Regeneca is
certain to be able to develop a strong niche in the nutraceutical market
with this terrific product.

Monday Nov. 9, 2009 Vivakor Announces Completion of Pilot Production
Evaluation of Nutraceutical Product with Consumer Product Specialist,
Regeneca International, Inc.

Vivakor Inc., announced it has completed a pilot product evaluation
program with consumer product specialist, Regeneca International, Inc.
(
www.regeneca.com). The product evaluation involved Vivakors proprietary
nutraceutical formulation derived from natural sources. Research has shown
that phytochemicals, vitamins, minerals, and fiber, all present in fruits
and vegetables, work synergistically to promote health and lower disease
risk. For this reason, many organizations, such as the National Cancer
Institute and The American Heart Association, recommend getting
phytochemicals from whole foods, such as fruits and vegetables. The Vivakor
product is a whole food supplement designed to deliver these essential
nutrients to the users in small, single dose units.

Regenecas President, Larry Walter gave his thoughts on the study.
Not only are the consumer study results impressive, but the overall
opportunity to work with the team of professionals at Vivakor gives us a
great deal of optimism for our future dealings with the company.

The parties plan additional studies with the hope of a market ready
product by early 2010.

Vivakor, Inc. is a transdisciplinary research company that develops
products in the fields of molecular medicine, electro-optics, biological
handling and natural and formulary compounds. The Company also provides
contract research services for third parties. Vivakor has developed
numerous products and have filed many patents or provisional patents with
the United States Patent and Trademark Office (USPTO). They intend to
commercialize such products, after completion of any required regulatory
approvals, through one of three methods: a sale of the technology,
licensing of the product to a manufacturer or distributor or, in some
cases, by manufacturing, marketing and directly selling the products
themselves.

Stay tuned for more News and Updates on VIVK this week!!!

Regards,

FHPS Staff

_____________________________________________________________________________

The disclaimer is to be read and fully understood before using our site,
or joining our email list.

See Free Hot Penny Stocks's website for full disclaimer. Free Hot Penny Stocks may have received compensation for stock picks.